Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study.
Ingrasciotta Y, Belleudi V, Trotta F, Addis A, Fontana A, Chinellato A, Ientile V, Tari DU, Roberto G, Pastorello M, Scondotto S, Cananzi P, Traversa G, Davoli M, Rossi M, Trifirò G; Italian Biosimilars Network (I-BioNetwork). Ingrasciotta Y, et al. Among authors: chinellato a. BioDrugs. 2020 Feb;34(1):55-64. doi: 10.1007/s40259-019-00385-y. BioDrugs. 2020. PMID: 31595485
Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents?
Ingrasciotta Y, Sultana J, Formica D, Ientile V, Aiello A, Chinellato A, Tari DU, Gini R, Pastorello M, Scondotto S, Cananzi P, Traversa G, Rossi M, Santoro D, Trifirò G; Italian Biosimilars Network (I-BioNetwork). Ingrasciotta Y, et al. Among authors: chinellato a. Pharmacoepidemiol Drug Saf. 2021 Jan;30(1):65-77. doi: 10.1002/pds.5152. Epub 2020 Nov 16. Pharmacoepidemiol Drug Saf. 2021. PMID: 33067914
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, Troncone C, Fontana A, Ientile V, Gini R, Santoro D, Santarpia M, Genazzani A, Uomo I, Pastorello M, Addario WS, Scondotto S, Cananzi P, Caputi AP, Trifirò G. Ingrasciotta Y, et al. Among authors: chinellato a. BioDrugs. 2015 Aug;29(4):275-84. doi: 10.1007/s40259-015-0132-7. BioDrugs. 2015. PMID: 26169209 Free PMC article.
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
Ingrasciotta Y, Giorgianni F, Marcianò I, Bolcato J, Pirolo R, Chinellato A, Ientile V, Santoro D, Genazzani AA, Alibrandi A, Fontana A, Caputi AP, Trifirò G. Ingrasciotta Y, et al. Among authors: chinellato a. PLoS One. 2016 May 17;11(5):e0155805. doi: 10.1371/journal.pone.0155805. eCollection 2016. PLoS One. 2016. PMID: 27187174 Free PMC article.
Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009-2014.
Marcianò I, Ingrasciotta Y, Giorgianni F, Ientile V, Chinellato A, Tari DU, Gini R, Cannavò S, Pastorello M, Scondotto S, Cananzi P, Traversa G, Trotta F, Belleudi V, Addis A, Trifirò G. Marcianò I, et al. Among authors: chinellato a. Front Endocrinol (Lausanne). 2018 Mar 13;9:95. doi: 10.3389/fendo.2018.00095. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 29593655 Free PMC article.
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
Marcianò I, Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Di Giorgio A, Manna S, Ientile V, Gini R, Santarpia M, Genazzani AA, Uomo I, Pastorello M, Pollina Addario SW, Scondotto S, Cananzi P, Da Cas R, Traversa G, Rossi M, Sottosanti L, Caputi AP, Trifirò G. Marcianò I, et al. Among authors: chinellato a. BioDrugs. 2016 Aug;30(4):295-306. doi: 10.1007/s40259-016-0175-4. BioDrugs. 2016. PMID: 27138636
All-cause mortality and antipsychotic use among elderly persons with high baseline cardiovascular and cerebrovascular risk: a multi-center retrospective cohort study in Italy.
Sultana J, Giorgianni F, Rea F, Lucenteforte E, Lombardi N, Mugelli A, Vannacci A, Liperoti R, Kirchmayer U, Vitale C, Chinellato A, Roberto G, Corrao G, Trifirò G. Sultana J, et al. Among authors: chinellato a. Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):179-188. doi: 10.1080/17425255.2019.1561860. Epub 2019 Jan 4. Expert Opin Drug Metab Toxicol. 2019. PMID: 30572727
Calcium Channel Blockers in Secondary Cardiovascular Prevention and Risk of Acute Events: Real-World Evidence from Nested Case-Control Studies on Italian Hypertensive Elderly.
Bettiol A, Lucenteforte E, Vannacci A, Lombardi N, Onder G, Agabiti N, Vitale C, Trifirò G, Corrao G, Roberto G, Mugelli A, Chinellato A; Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Bettiol A, et al. Among authors: chinellato a. Clin Drug Investig. 2017 Dec;37(12):1165-1174. doi: 10.1007/s40261-017-0576-2. Clin Drug Investig. 2017. PMID: 28975522
82 results